Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A.
Garje R, Hope TA, Rumble RB, Parikh RA; Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Guideline Expert Panel. Garje R, et al. Among authors: parikh ra. JCO Oncol Pract. 2023 Mar;19(3):132-135. doi: 10.1200/OP.22.00753. Epub 2023 Jan 24. JCO Oncol Pract. 2023. PMID: 36693228 No abstract available.
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
Garje R, Rumble RB, Parikh RA; Systemic Therapy Update on177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Guideline Expert Panel. Garje R, et al. Among authors: parikh ra. J Clin Oncol. 2023 Nov 6:JCO2302128. doi: 10.1200/JCO.23.02128. Online ahead of print. J Clin Oncol. 2023. PMID: 37931186
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Ivy SP, Van Allen EM, Lindeman NI, Kochupurakkal BS, Shapiro GI, McKay RR. Pan E, et al. Mol Cancer Ther. 2023 Apr 3;22(4):511-518. doi: 10.1158/1535-7163.MCT-22-0583. Mol Cancer Ther. 2023. PMID: 36780008 Free PMC article. Clinical Trial.
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. Sadeghi S, et al. J Clin Oncol. 2023 Jan 20;41(3):640-650. doi: 10.1200/JCO.21.02923. Epub 2022 Aug 19. J Clin Oncol. 2023. PMID: 35984996 Clinical Trial.
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN Jr. Sadeghi S, et al. J Clin Oncol. 2019 Oct 10;37(29):2682-2688. doi: 10.1200/JCO.19.00861. Epub 2019 Aug 7. J Clin Oncol. 2019. PMID: 31390274 Free PMC article. Clinical Trial.
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Appleman LJ, et al. Among authors: parikh ra. J Clin Oncol. 2024 Mar 26:JCO2301544. doi: 10.1200/JCO.23.01544. Online ahead of print. J Clin Oncol. 2024. PMID: 38531002
40 results